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Objectives: Our aim was to investigate CD4+ cell recovery and adverse outcome after highl
active antiretroviral therapy (HAART) under the Peruvian National Program for HIV.
Methods: A prospective, observational study was conducted between May 2004 and Septembe
2005. Data were collected from records of patients receiving HAARTat a public hospital under th
Peruvian National Program for HIV. Predictors of CD4+ cell count recovery and adverse outcom
were analyzed by multiple regression.
Results: Three hundred and twenty-six patients were included in the study. The mean increase i
CD4+ cell count at six months was 114 cells/ml (95% confidence interval: 103—126). Patients wit
a lower CD4+ cell count at baseline and those starting HAARTwith a didanosine-based regimen ha
a higher increase in CD4+ cell count at six months. Patients starting HAARTwith a stavudine-base
regimen had a lower increase in CD4+ cell count at six months. World Health Organization clinica
stage IV at diagnosis of HIV infection, a low body weight at baseline, and starting HAARTwith
stavudine-based regimen were independently associated with an adverse outcome.
Conclusions: The CD4+ cell response to HAART under the Peruvian National Program for HIV wa
comparable with reports from other countries. However, the fact that advanced clinical diseas
predicted adverse outcome emphasizes the need for earlier access to HAART.
# 2007 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved* Corresponding author. Tel.: +51 1 482 3910, 482 3903; fax: +51 1 482 3404.
E-mail address: 09326@upch.edu.pe (D. Lo´pez de Castilla).
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Since the introduction of highly active antiretroviral therapy
(HAART) ten years ago, HIV-related morbidity and mortality
have decreased substantially in the industrialized world.1—4
However, global HIV-related mortality has continued to rise.
By 2000, more than 90% of HIV cases and deaths occurred in
developing countries where less than 10% of people living
with HIV/AIDS had access to HAART.5,6 In 2002, the Global
Fund to Fight AIDS, Tuberculosis and Malaria was launched,
and has approved nearly 450 grants in 136 countries.7
New evidence supports the implementation of national
programs, suggesting lower mortality rates in settings where
HAART is provided free of charge.8 Up until May 2007, 28 941
cases of HIVand 19 828 cases of AIDS had been reported to the
Peruvian Ministry of Health.9 The HIV epidemic in Peru is still
considered a ‘concentrated epidemic’10 given that it pre-
dominantly affects high-risk groups and occurs in less than 1%
of the general population;11,12 however, 68% of all AIDS cases
are concentrated in Lima.9
Free access to HAART became available with the inaugu-
ration of the Peruvian National Program (NP) in May 2004 with
the financial aid of the Global Fund. Peruvian HIV patients are
often diagnosed at an advanced stage of the disease,13 with
CD4+ cell counts below 100 cells/ml and with irregular expo-
sure to antiretroviral therapy (ART). Both advanced disease
and previous exposure to ART (which has been linked with
ART resistance)14 have been associated with reduced treat-
ment efficacy.15,16 However, in several developing countries
where patients start HAARTat an advanced stage of immune
suppression, consistent short-term rises in CD4+ counts have
been reported.17,18 Information on the CD4+ cell response
during HAART under the Peruvian NP is very limited and of
extreme relevance as it will guide further decision-making in
the program. Our aim was to study predictors for CD4+ cell
recovery and adverse outcome in patients after 6 months of
HAART under the Peruvian NP.
Methods
Setting
The Infectious DiseaseClinic at theHospitalNacional Cayetano
Heredia (HNCH) in collaborationwith the Instituto deMedicina
Tropical Alexander von Humboldt (IMTAvH) of the Universidad
Peruana Cayetano Heredia (UPCH), is a national referral cen-
ter for HIV diagnosis and management. It receives more than
5000 HIV-related outpatient visits and diagnoses approxi-
mately 400 HIV cases per year.19 Currently 5892 patients
receive HAART subsidized by the NP; our institution cares
for 18% them. According to the Ministry of Health, in order
to start HAARTwithin the NP, patients should be: (1) sympto-
matic or (2) asymptomatic with a CD4+ cell count below
200 cells/ml or a plasma viral load above 55 000 copies/mm3.
The NP coordinates appointments for baseline and follow-
up CD4+ cell count and viral load measurements at the
laboratories of the Peruvian National Institute of Health,
although only half of our patients have viral load results
available.19 The NP provides fixed doses of generic antire-
troviral drugs, given their lower cost. Four nucleoside ana-
logue reverse transcriptase inhibitors (NRTI; zidovudine(AZT), didanosine (ddI), stavudine (d4T), and lamivudine
(3TC)), two non-nucleoside analogue reverse transcriptase
inhibitors (NNRTI; nevirapine (NVP) and efavirenz (EFV)), and
two protease inhibitors (PI; lopinavir/ritonavir and indinavir)
are available. NP guidelines recommend AZT + 3TC + NVP as
the first-line regimen.20 If the first-line regimen is contra-
indicated due to a high risk of toxicity, previous treatment
failure, or by an expert panel decision, other regimens can be
used.
Study population
HIV-infected individuals who received antiretroviral therapy
at HNCH and who were 18 years of age, had started HAART
within the NP between May 2004 and September 2005, and
who had not been receiving any antiretroviral drug by other
means when they started HAARTwithin the NP, were eligible
for this study. However, previous use of an antiretroviral drug
was not an exclusion criterion. Patients were excluded if they
were transferred to another health service within the first six
months of treatment. To evaluate CD4 + cell increase and
associated factors, we excluded all patients who did not have
CD4+ cell counts at baseline and at six months. We also
analyzed the determinants of an adverse outcome, which
we defined as: (1) dying, (2) not achieving any increase in the
absolute number of CD4+ lymphocytes after six months of
HAART, or (3) abandoning treatment within the first six
months.
Procedures
Medical records, laboratory results, and patient treatment
files were retrieved and reviewed by the IMTAvH research
group. We registered the following variables: sex, age, World
Health Organization (WHO) clinical stage at diagnosis of HIV
infection, ARTuse before enrolment in the NP, baseline CD4+
cell count, weight, hematocrit, and first ART regimen pre-
scribedwithin the NP. Clinical and laboratory values measured
up to 6 months before and 14 days after the date of enrolment
were considered as baseline values. For those with more than
one measurement during this period, the one closest to the
date of HAART prescription was chosen. For CD4+ cell count
monitoring, measurements between 5 and 7 months after
enrolment were considered as the 6th month value. CD4+ cell
counts were determined by either a FACSCaliburTM flow cyt-
ometer instrument (Becton Dickinson and Company, Franklin
Lakes, New Jersey, USA) or a FACSCountTM flow cytometer
instrument (Becton Dickinson); the former is used at the
Peruvian National Institute of Health and the latter is used
at the IMTAvH for research and service purposes.
Statistical analysis
We computed the mean and 95% confidence interval (CI) of
the increase in CD4+ lymphocytes after six months of HAART.
To evaluate the effect of the baseline factors on this
increase, we used bivariate correlation and Student’s t-tests.
All factors with significant results ( p < 0.05) were then
included in a multiple linear regression model. Through
backward elimination, the factors that did not contribute
significantly to the prediction of the increase in CD4+ cell
CD4+ cell count response with HAART, Peru 327
Figure 1 Flow chart showing the number of eligible subjects,
and the number of subjects included in the CD4+ cell increase
and adverse outcome analyses.counts were removed. In a further analysis, we identified
baseline factors associated with adverse outcome. Chi-
square, Fisher’s exact, and Student’s t-tests were used for
bivariate evaluations. Crude odds ratios (OR) and 95% CI were
also determined. Factors with p < 0.2 on univariate analysis
were included in a logistic regression analysis. Data were
stored in Microsoft Access and analyzed with SPSS for Win-
dows version 13.0 (SPSS, Inc., Chicago, IL, USA).
Ethical considerations
The study was approved by the Institutional Review Board at
the Universidad Peruana Cayetano Heredia.Table 1 Baseline characteristics of patients included in and exc
Characteristic a Patien
Male sex, n (%) 230 (7
Age in years, mean (SD) 36 (1
WHO clinical stage IV at diagnosis of HIV infection, n (%) 223 (6
ART experienced, n (%) 91 (2
Weight in kg, mean (SD) 57 (1
Hematocrit %, mean (SD) 34 (6
CD4+ cell count, median (IQR) 78 (1







Protease inhibitor 32 (1
SD, standard deviation; IQR, interquartile range; ART, antiretroviral th
a At the time of enrolment in the national program, unless otherwise
b Chi-square test, continuity correction.
c Student’s t-test.
d Mann—Whitney U-test.
e Fisher’s exact test.Results
Of the 469 patients who were eligible, 326 (70%) were
included in the study. Of these, 47 (14%) died, 14 (4%)
abandoned treatment, and 265 (81%) had baseline and fol-
low-up CD4+ cell counts (Figure 1). The remaining 143
patients (30%) were excluded from all analyses: three
patients because they were transferred to another health
service, 38 due to missing CD4+ cell counts at baseline, and
102 due to missing CD4+ cell counts at six months (Figure 1).
Patient characteristics
Themajority (71%) of the 326 patients included in one or both
of the analyses were men (Table 1). The mean age was 36
years (standard deviation (SD): 10 years). The median base-
line CD4+ cell count was 78 cells/ml (interquartile range
(IQR): 139). Of the 326 study patients, 292 (90%) started
on an NNRTI-based regimen (93% with NVP and 7% with EFV).
The remaining patients started with a PI-based regimen.
Among the included patients, the proportion of men was
71% (230/326) compared to 61% (87/143) among the subjects
excluded from all analyses. This difference was of borderline
significance ( p = 0.05); there were no other differences
between the study patients and the excluded subjects
(Table 1).
Factors associated with CD4+ cell count increase
Two hundred sixty-five patients had baseline and follow-up
values of CD4+ cell counts, and 215 (81%) of these had a CD4+
cell count below 200 cells/ml. After six months, 98 of them
(46%) reached a CD4+ cell count of 200 cells/ml or more. The
mean increase was 114 cells/ml (95% CI: 103—126). On bivari-
ate analysis we observed that those who started HAART in theluded from the study
ts included (N = 326) Patients excluded (N = 143) p-Value
1) 87 (61) 0.05b
0) 35 (9) 0.3c
8) 101 (71) 0.7b
8) 51 (36) 0.1b
1) 58 (10) 0.4c
) 35 (5) 0.6c
39) 78 (129) 0.6d
5) 120 (84) 0.8b
) 10 (7) 1.0b
0) 113 (79) 1.0b
8) 141 (99) 1.0e
1) 16 (11) 1.0b
) 17 (12) 0.3b
0) 13 (9) 0.9b
erapy.
indicated.
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Table 2 Multivariate analysis for predictors of CD4+ count increase (N = 265)
Explanatory variables in the final model a B Standard error Significance Tolerance
Constant 141.7 8.2 <0.001
Baseline CD4+ cell count 0.2 0.05 <0.001 0.89
Stavudine-containing regimen 54.9 22.9 0.02 0.91
Didanosine-containing regimen 53.6 20.7 0.01 0.97
B = unstandardized regression coefficient.
a The initial model contained five explanatory variables: baseline CD4+ cell count, previous use of antiretrovirals, stavudine-containing
regimen, didanosine-containing regimen, and hematocrit (R2: 0.15 and adjusted R2: 0.13). Through backward selection, hematocrit and
previous use of antiretrovirals were removed (final R2: 0.15 and adjusted R2: 0.14).NP with lower CD4+ cell counts had a larger increase (Spear-
man correlation coefficient: p = 0.01). Patients with a
low baseline hematocrit also showed a larger increase in
CD4+ cell counts (Pearson correlation coefficient: p = 0.04).
Those who had been exposed to ART before their enrolment
in the NP had a mean increase of 93 cells/ml compared to
123 cells/ml among treatment-naı¨ve subjects (Student’s t-
test: p = 0.04). Patients starting a didanosine-based regimen
had amean increase of 150 cells/ml compared to 110 cells/ml
among patients who received other regimens (Student’s t-
test: p < 0.05). On the other hand, subjects starting with a
stavudine-containing regimen had a smaller increase in CD4+
cell counts (mean 41 cells/ml compared to 121 cells/ml
among patients starting on a regimen without stavudine;
Student’s t-test: p = 0.02). We found no significant associa-
tion between mean increase in CD4+ cell count and sex, age,
WHO stage at diagnosis, weight, and the use of any of
the other antiretroviral drugs in the first treatment regimen.
On multiple linear regression analysis, the association
with baseline CD4+ cell count, didanosine, and stavudineTable 3 Bivariate and multivariate analysis for predictors of adv
Characteristic a Treatment
success (N = 237)
Male sex, n (%) 170 (72)
Age in years, mean (SD) 35.5 (9.9)
WHO clinical stage IV at
diagnosis of HIV infection, n (%)
154 (65)
ART experienced, n (%) 65 (27)
Weight in kg, mean (SD) 58.4 (11.1)
Hematocrit %, mean (SD) 34.9 (5.5)
Baseline CD4+ cell count <100, n (%) 131 (55)







Protease inhibitor 22 (9)
OR, odds ratio; CI, confidence interval; SD, standard deviation; ART, a
a At the time of enrolment in the national program, unless otherwis
b Multiple logistic regression analysis, backward stepwise approach. Va
CD4+ count, stavudine, zidovudine, and didanosine. Nagelkerke R2: 0.
c Baseline CD4+ cell counts were missing in nine subjects with treatmremained significant. The model based on these three vari-
ables explained 14% of the variation in CD4+ cell increase
(Table 2).
Factors associated with an adverse outcome
Of all the patients included in the study, 28% met the criteria
for an adverse outcome (47 died, 14 abandoned treatment,
and 28 had a decrease in CD4+ cell count). The bivariate
analysis showed that baseline weight, hematocrit, and WHO
clinical stage IV at the time of diagnosis of HIV infection were
significantly associated with an adverse outcome (Table 3).
Starting an AZT- or d4T-based treatment regimen was also
associated with an adverse outcome. On multiple logistic
regression analysis, the following factors remained signifi-
cantly associatedwith anadverse outcome:WHOclinical stage
IV at diagnosis of HIV infection (adjusted OR 2.8, 95% CI: 1.2—
6.4), low baseline weight (adjusted OR 0.96 per kg increase in
baseline weight, 95% CI: 0.93—0.99), and starting a stavudine-
based regimen (adjusted OR 4.9, 95% CI: 1.9—12.5).erse outcome
Treatment





60 (67) 0.8 (0.5—1.4) —
35.9 (8.9) 1.00 (0.98—1.03) —
69 (78) 1.9 (1.1—3.3) 2.8 (1.2—6.4)
26 (29) 1.1 (0.6—1.9) —
53.3 (11.3) 0.96 (0.94—0.98) 0.96 (0.93—0.99)
32.7 (7.0) 0.94 (0.90—0.98) —
53 (66) c 1.6 (0.9—2.7) —
75 (84) 0.9 (0.5—1.8) —
5 (6) 0.7 (0.3—2.0) —
61 (69) 0.4 (0.2—0.7) —
88 (99) 1.9 (0.2—16.5) —
14 (16) 1.8 (0.9—3.7) —
14 (16) 3.0 (1.4—6.5) 4.9 (1.9—12.5)
10 (11) 1.2 (0.6—2.7) —
ntiretroviral therapy.
e indicated.
riables entered on step 1: weight, WHO stage, hematocrit, baseline
15.
ent failure.
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stavudine-based regimen, there were no significant differ-
ences in baseline characteristics compared to the patients
who started with other regimens (data not shown). Seven-
teen of these patients had anemia at the start of HAART, and
eleven patients weighed less than 60 kg and might have
received a higher dose of stavudine for their body weight.
The most frequent drugs in the stavudine-based regimen
were lamivudine and nevirapine (16/28), followed by lami-
vudine and lopinavir/ritonavir (7/28), lamivudine and efa-
virenz (2/28), and three patients took an individualized PI-
based regimen. Four out of the 22 patients who survived six
months after starting HAART had their treatment regimen
changed within this period.Discussion
This study shows that a good immunological response can be
achieved after 6 months of HAARTunder the Peruvian NP. The
mean increase in CD4+ count was higher than 100 cells/ml.
Larger rises were observed in patients who started HAART
with lower CD4+ cell counts. We also observed that a dida-
nosine-based regimen was associated with a greater increase
in CD4+ cell count. Patients who started a stavudine-based
regimen had a smaller increase in CD4+ cell count. Also, when
we took an adverse outcome as the endpoint, there was an
association with stavudine-containing regimens. A low body
weight at baseline and WHO clinical stage IV at the time of
HIV diagnosis were independently linked to an adverse out-
come.
The immunological response we found is consistent with
mean CD4+ rises of 65—143 cells/ml described in other set-
tings.2,15,17,18,21—25 In a report on patients from 11 countries
who attended HIV/AIDS programs conducted by Doctors With-
out Borders/Me´decins Sans Frontie`res (MSF), who started
HAART at advanced stages of disease (median CD4+ cell
counts 89 cells/ml) and received a generic fixed dose combi-
nation (d4T, 3TC, NVP), the median increase after six months
of HAART was 102 cells/ml.21 Furthermore, a recent meta-
analysis on the efficacy of HAART programs in resource-poor
settings showed rises in CD4+ counts between 74 and
288 cells/ml.26 Our patients had low CD4+ counts before
starting HAART. However, the inverse correlation between
the baseline CD4+ cell count and its increase at 6 months
demonstrates that patients at higher risk of disease progres-
sion can rapidly recover their immune function after initiat-
ing HAART.15 A good immunological response to HAART is
associated with a good prognosis despite poor pre-treatment
values. The most remarkable increase in CD4+ cell counts has
been described between the first and the third month after
starting HAART; the overall increase achieved thereafter is
smaller.27—30
A stavudine-based regimen was associated with a lower
increase in CD4+ cell count andwith an adverse outcome; this
is in contrast to several clinical trials that have not found
regimens containing zidovudine to be superior to stavudine
with regard to immunological or virological response.31—37
We reviewed the complete clinical files of the 28 patients
who started HAARTwith a stavudine-containing regimen but
were unable to explain, based on the clinical information,
why an adverse outcome was so frequent in this group.Advanced stage HIV disease at diagnosis was associated
with an adverse outcome, i.e., patients with a late diagnosis
had a higher death rate, a lower immunological response, or a
higher rate of treatment abandonment in the first six months
of HAART. This is in accordance with observations in other
settings.2,18,21,38 In a community health center in Cape Town,
advancedWHO clinical stage at diagnosis was associated with
mortality within 4 months of starting HAART.38 There was no
association with later mortality.
In a large study comparing data from low- and high-income
countries, similar immunological and virological responses
after 6 months of starting HAARTwere found, but in the same
period, mortality during treatment was substantially higher
in patients from low-income settings.8
We found an association between low baseline CD4+
counts and an adverse outcome in the univariate analysis
but the factor did not remain significant in the multivariate
analysis. Nevertheless, several studies report that low base-
line CD4+ counts are associated with death or poor out-
come.2,7,21,38 A low baseline weight was an independent
predictor of an adverse outcome in our study, which is in
agreement with other observational studies where patients
with a body mass index under 18 kg/m2 had a two-fold
increased risk of dying.21 Our model did not find differences
in immune response to HAART with respect to age, which
contrasts with other observations, even in similar popula-
tions.22,29,39,40
This study has several limitations. We could not include
some pre-treatment characteristic factors known to affect
CD4+ increase, such as viral load and co-existing opportunis-
tic infections, because these data were available only for a
small number of patients. In addition, the information on
previous use of ARTwas not based on clinical records but on
patient interview, which may have affected its reliability.
Finally, 30% of the population was not included in the analysis
because CD4+ counts were lacking either at baseline or at six-
month follow-up.
In conclusion, the immunological response to HAART
under the Peruvian NP was found to be comparable with
reports from industrialized countries. The fact that
advanced clinical disease predicts an adverse outcome as
outlined by this and other studies, clearly emphasizes the
need for earlier access to HAART in order to optimize the
response to therapy.
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